This is a blood disorder that affects the production of hemoglobin, a protein in red blood cells. It's caused by missing genes that make the alpha chains of hemoglobin. The severity can range from mild to severe anemia.
Every report comes from a Lived member, sent anonymously.
Have you tried Blood transfusion therapy for Alpha-Thalassemia?
Alpha-thalassemia is an inherited blood disorder in which the body makes too little alpha-globin, one of the protein chains that make up hemoglobin. Hemoglobin is the protein inside red blood cells that carries oxygen. With less of it, red blood cells tend to be smaller and paler than usual, and some people develop anemia (too few healthy red blood cells), which can cause tiredness, weakness and pale skin. People normally have four genes that make alpha-globin, two inherited from each parent, and how severe alpha-thalassemia is depends largely on how many of them are missing or altered. With one affected gene, a person is a silent carrier and typically has no signs at all. With two, they have alpha-thalassemia trait (also called alpha-thalassemia minor), which may cause mild anemia but usually no health problems. With three, they usually have hemoglobin H (HbH) disease, which causes lifelong mild to moderate anemia, sometimes more severe. When all four are affected, the result is hemoglobin Bart hydrops fetalis syndrome, a serious condition that develops before birth.
Alpha-thalassemia is genetic. It is usually caused by missing pieces (deletions) of the alpha-globin genes, and less often by smaller changes in those genes, called non-deletional variants. Non-deletional changes tend to reduce alpha-globin more, so they can produce HbH disease even when only two of the four genes are affected. Nothing a person does causes alpha-thalassemia, and it cannot be prevented once inherited. Because each parent passes on two of the four genes, two people who both carry alpha-thalassemia can have children with a more severe form than either parent has. The exact chances depend on how many genes each parent is missing and how those missing genes are arranged. Alpha-thalassemia is common worldwide and especially frequent in people with roots in Southeast Asia, the Mediterranean, Africa, the Middle East, India and Central Asia. For people with HbH disease, some things can temporarily make anemia worse. Infections can trigger episodes of rapid red blood cell breakdown (hemolysis), and so can certain oxidant medicines, the same ones avoided by people with G6PD deficiency, an inherited enzyme shortage that also makes red cells fragile.
Milder forms are often discovered by chance, when a routine complete blood count (CBC) shows red blood cells that are smaller than normal, sometimes with slightly low hemoglobin. Small red blood cells are also a hallmark of iron deficiency, so clinicians usually check iron levels to tell the two apart. Special hemoglobin tests measure the different types of hemoglobin in the blood and can detect the abnormal hemoglobin H found in HbH disease. Genetic testing confirms the diagnosis and shows how many alpha-globin genes are affected and in what way, which matters for both treatment and family planning. HbH disease usually becomes apparent in early childhood, but some people are not diagnosed until adulthood. More serious forms are often picked up by newborn screening. Because a couple who both carry alpha-thalassemia can have a severely affected baby, screening is recommended before or early in pregnancy for people from populations where it is common, along with genetic counseling when both partners are carriers. Prenatal testing can show whether a pregnancy is affected and can be done as early as 8 to 10 weeks.
Silent carriers and people with alpha-thalassemia trait usually need no treatment. The most useful practical point for them is that their small red blood cells are not caused by low iron, so iron pills will not help unless tests show a true iron deficiency as well. Knowing carrier status also matters when planning a family. HbH disease is managed with monitoring and targeted care rather than routine treatment. Many people with HbH disease stay well without regular treatment, while some, especially those with non-deletional forms, need transfusions more often or on a regular schedule. Folic acid supplements are recommended to support red blood cell production. Red blood cell transfusions may be needed during infections, surgery, pregnancy or other times when anemia suddenly worsens. Avoiding unnecessary iron supplements and oxidant medicines helps prevent problems, so it is worth asking a pharmacist or clinician before starting a new drug. Even without transfusions, people with HbH disease absorb more iron from food than they need, and over years this extra iron can build up and damage the liver, heart and hormone-producing glands. Iron levels are checked with a blood test called ferritin and sometimes with an MRI of the liver. When iron is too high, chelation medicines, which bind excess iron so the body can remove it, are used. Gallstones are common because of ongoing red cell breakdown, and some people need gallbladder surgery. Removing the spleen is usually avoided because it raises the risk of blood clots. Mitapivat (Aqvesme) is a daily pill approved for anemia in adults with alpha- or beta-thalassemia. It boosts the activity of an enzyme red blood cells rely on for energy. In studies, it raised hemoglobin and eased fatigue more than a placebo in adults who did not need regular transfusions, and helped a minority of transfusion-dependent adults cut their transfusions by half or more. It can cause serious liver injury, so it is available only through a restricted program that requires liver blood tests every 4 weeks for the first 24 weeks. For hemoglobin Bart hydrops fetalis syndrome, blood transfusions given to the baby in the womb can allow survival, followed by regular transfusions after birth. A stem cell transplant from a matched donor is the only treatment that can cure the condition, but it is considered only for severe disease, and few people have a suitable donor and are good candidates for the procedure.
Silent carriers and people with alpha-thalassemia trait typically live normal, healthy lives. The diagnosis matters mainly for avoiding unnecessary iron treatment and for understanding the chances of passing on a more severe form. People with HbH disease usually live into adulthood, and many feel reasonably well for long stretches, but the condition is lifelong and its course varies widely. Expect regular follow-up with a hematologist (a blood specialist), typically blood counts every 6 to 12 months, checks of growth and development in children, and periodic monitoring of iron levels. Anemia can dip suddenly during infections, so some people need an occasional transfusion even if they have never needed one before. Pregnancy needs extra planning for anyone with HbH disease. Anemia can worsen, and the risks of preeclampsia (high blood pressure in pregnancy), heart strain and miscarriage are higher, so closer monitoring with an obstetric and hematology team is recommended. Partner testing before conception helps clarify whether a pregnancy could be affected by a more severe form.
Talk to a clinician if blood tests have shown small red blood cells or mild anemia that has not improved with iron, or if you or your partner has alpha-thalassemia or a family history of it and you are planning a pregnancy. If you or your child has HbH disease, contact the care team right away with a fever or other sign of infection, or if you notice increasing paleness or tiredness, yellowing of the skin or eyes, or dark urine, since these can signal a rapid drop in red blood cells that may need a transfusion. Shortness of breath, dizziness or fainting with known HbH disease needs to be seen by a clinician the same day.
Last reviewed • Oct 2026
Educational content, not medical advice.
Anyone else find out during pregnancy they had alpha-thalassemia minor? Diagnosis changed my life after finding out.